文献速递肝病消化道肿瘤与早癌

慢性乙型肝炎免疫耐受期患者肝细胞癌发生风险极低

Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase.
PubMed 文献 · Aliment Pharmacol Ther · 2020-05-26

该研究纳入946例免疫耐受期慢性乙型肝炎患者,随访中位63.6个月,10年阶段转变累积发生率为70.7%,肝细胞癌累积发生率仅1.7%。HBV-DNA>10^7 IU/mL与阶段转变风险降低独立相关,而ALT高于韩国指南cut-off与阶段转变风险增加独立相关。

要点

  • 免疫耐受期CHB患者10年HCC累积发生率仅1.7%。
  • HBV-DNA>10^7 IU/mL与阶段转变风险降低独立相关。
  • ALT高于韩国指南cut-off与阶段转变风险增加独立相关。

核心结论

  • 免疫耐受期CHB患者肝细胞癌发生风险极低。
  • HBV-DNA>10^7 IU/mL可能有助于定义免疫耐受期。

研究设计与样本

  • 多中心回顾性队列研究,纳入1989至2017年8家机构的946例免疫耐受期CHB患者。
  • 免疫耐受期定义为HBeAg阳性、HBV-DNA>20 000 IU/mL且ALT≤40 IU/L。

主要发现

  • 研究人群平均年龄36.7岁,男性429例、女性517例。
  • 平均ALT为24.6 IU/L,平均HBV-DNA为8.50 log10 IU/mL。
  • 476例(50.3%)在整个研究期间保持免疫耐受期,中位随访63.6个月。
  • 10年阶段转变累积发生率为70.7%,10年HCC累积发生率为1.7%。
  • 多因素分析显示HBV-DNA>10^7 IU/mL与阶段转变风险降低独立相关(HR=0.734,P=0.008)。

关键数值与推荐

  • 免疫耐受期定义:HBeAg阳性、HBV-DNA>20 000 IU/mL、ALT≤40 IU/L。
  • 韩国肝病学会指南ALT cut-off:男性34 IU/L,女性30 IU/L。

临床怎么用

  • 免疫耐受期CHB患者HCC风险极低,支持抗病毒治疗非指征的现有观点。
  • HBV-DNA>10^7 IU/mL可辅助界定免疫耐受期。
  • ALT高于韩国指南cut-off提示阶段转变风险增加,需加强监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-viral therapy is not indicated for patients with chronic hepatitis B (CHB) in the immune-tolerant phase. AIMS: To investigate the cumulative incidence of phase change and hepatocellular carcinoma (HCC) and independent predictors for phase change in patients with CHB in immune-tolerant phase. METHODS: In total, 946 patients in immune-tolerant phase, defined as hepatitis B e antigen positivity, HBV-DNA >20 000 IU/mL and alanine aminotransferase (ALT) ≤40 IU/L, between 1989 and 2017 were enrolled from eight institutes. RESULTS: The mean age of study population (429 men and 517 women) was 36.7 years. The mean ALT and HBV-DNA levels were 24.6 IU/L and 8.50 log10 IU/mL, respectively. Of the study population, 476 (50.3%) patients remained in immune-tolerant phase throughout the study period (median: 63.6 months). The cumulative incidence rates of phase change and HCC at 10 years were 70.7% and 1.7%, respectively. Multivariate analyses revealed that HBV-DNA level >107 IU/mL was associated independently with a reduced risk of phase change (hazard ratio [HR] = 0.734, P = 0.008), whereas a high ALT level, above the cut-off recommended in the Korean Association for the Study of the Liver guidelines (34 IU/L for men and 30 IU/L for women), was associated independently with a greater risk of phase change (HR = 1.885, P < 0.001). CONCLUSIONS: The criterion of HBV-DNA level > 107 IU/mL may be useful to define immune-tolerant phase. In addition, an extremely low risk of HCC development was observed in patients with CHB in immune-tolerant phase.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lee HA, Lee HW, Kim IH, et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. Aliment Pharmacol Ther. 2020. PMID: 32452564. doi:10.1111/apt.15741

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。